One stock you can’t skip: Bionano Genomics Inc. [BNGO]

Bionano Genomics Inc. (BNGO) stock prices have grown nearly 1,000% in the past 12 months. Despite this, some analysts feel that the shares have already reached their peak and are unlikely to grow rapidly soon. The shares of the company fell more than 12% to $11.85 on February 22.

BNGO’s share price has increased by 967.57% since the start of this year. During the last five trades, the stock price dropped -13.50%, while the stock price rose 43.29% during the last 30 trades. The share price added 2202.31% to its price during the previous three months, while the price rose 1631.95% over the last six months.

The main product of Bionano Genomics is Saphyr lab equipment, which can detect large structural variations and aberrations of chromosomes, which are not detectable by standard gene sequencers. Presently, this equipment are used to diagnose all sorts of neurological conditions, including Alzheimer’s disease, leukaemia, COVID-19, hepatocellular carcinoma, and Lou Gehrig’s disease.

This company’s total address market can reach $4 billion per year. In contrast, Wall Street analysts estimate that by 2020, Bionano Genomics’ revenue will be about $8 million. Company revenue is likely to be in the range of 18 – 19 million dollars this year.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Since Bionano Genomics’ Saphyr lab equipment is not directly a competitor to sequencers from other manufacturers because it is designed to detect different kinds of aberrations in chromosomes, competitive risks are relatively low. Moreover, Bionano Genomics must devote substantial resources to promoting its products to convince medical centres of the need for such purchase. That is why high costs and volatile sales dropped by a third in the last quarter. Yet, we can’t deny that Bionano Genomics is on a path to becoming a leader.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Recent Articles

Intel (INTC) Intends to appeal against Court order for Violation of VLSI Tech

In the last quarter, Intel's (INTC) share price rose 29%. On Tuesday, Intel fell 2.6% after Federal Judge Jim Davis ruled the company must...

The Facts You Need to Know about Itron Inc. (ITRI) Moving Forward

Itron, Inc. (NASDAQ: ITRI) released a positive update for the fourth quarter and full-year 2020. This quarter was highlighted by a record portfolio of...

One stock you can’t skip: Bionano Genomics Inc. [BNGO]

Bionano Genomics Inc. (BNGO) stock prices have grown nearly 1,000% in the past 12 months. Despite this, some analysts feel that the shares have...

What the sentiment indicator is Signaling: CEVA Inc (CEVA)

CEVA, Inc. (NASDAQ: CEVA) reported its fourth-quarter report on Tuesday, February 16; the company signed 21 new agreements generating record revenues. CEVA provides OEMs with...

A Stock Check: Which direction Pinterest Inc (PINS) will move from here?

The social networking company Pinterest Inc (PINS) rose 226% in the past year. If the price has increased significantly, is it worthwhile to acquire...

Related Stories

Leave A Reply

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.